Travere Therapeutics, Inc. Insider Trading Activity

Travere Therapeutics (TVTX) reported insider activity by its SVP & Chief Accounting Officer on 11/04/2025.

Accepted by SEC EDGAR 11/06/2025 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics (TVTX) reported insider activity by its SVP & Chief Accounting Officer on 11/04/2025. The officer exercised multiple employee stock options and sold shares pursuant to a Rule 10b5-1(c) plan adopted on June 10, 2025.

Exercises: 10,000 shares at $25.25; 17,500 at $26.88; 15,000 at $27.50; 12,500 at $22.40; and 6,250 at $8.93. Sale: 67,115 shares at $36. Following these transactions, beneficial ownership stood at 48,545 shares directly.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 11 txns

Insider Calvin Sandra

Role SVP, CHIEF ACCOUNTING OFFICER

Sold 67,115 shs ($2.42M)

Approx. gross sale proceeds $2.42M

Approx. exercise cost $1.47M

Share of Position Sold 58.0%

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	10,000	$0.00	$0.00
Exercise	Employee stock option (right to buy)	17,500	$0.00	$0.00
Exercise	Employee stock option (right to buy)	15,000	$0.00	$0.00
Exercise	Employee stock option (right to buy)	12,500	$0.00	$0.00
Exercise	Employee stock option (right to buy)	6,250	$0.00	$0.00
Exercise	Common Stock	10,000	$25.25	$253K
Exercise	Common Stock	17,500	$26.88	$470K
Exercise	Common Stock	15,000	$27.50	$413K
Exercise	Common Stock	12,500	$22.40	$280K
Exercise	Common Stock	6,250	$8.93	$56K
Sale	Common Stock	67,115	$36.00	$2.42M

Holdings After Transaction: Employee stock option (right to buy) — 28,750 contracts (Direct); Common Stock — 48,545 shares (Direct)

Holdings Before and After: Employee stock option (right to buy), 90,000 to 28,750 contracts (Direct); Common Stock, 54,410 to 48,545 shares (Direct)

Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (5)

1. F1. This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
2. F2. The stock option is fully vested and exercisable.
3. F3. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
4. F4. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
5. F5. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Calvin Sandra

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/04/2025		M		10,000	A	$25.25	64,410	D
Common Stock	11/04/2025		M		17,500	A	$26.88	81,910	D
Common Stock	11/04/2025		M		15,000	A	$27.5	96,910	D
Common Stock	11/04/2025		M		12,500	A	$22.4	109,410	D
Common Stock	11/04/2025		M		6,250	A	$8.93	115,660	D
Common Stock	11/04/2025		S(1)		67,115	D	$36	48,545	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$25.25	11/04/2025		M			10,000	(2)	05/10/2028	Common Stock	10,000	$0	0	D
Employee stock option (right to buy)	$26.88	11/04/2025		M			17,500	(2)	01/21/2031	Common Stock	17,500	$0	0	D
Employee stock option (right to buy)	$27.5	11/04/2025		M			15,000	(3)	01/31/2032	Common Stock	15,000	$0	2,500	D
Employee stock option (right to buy)	$22.4	11/04/2025		M			12,500	(4)	01/31/2033	Common Stock	12,500	$0	7,500	D
Employee stock option (right to buy)	$8.93	11/04/2025		M			6,250	(5)	01/31/2034	Common Stock	6,250	$0	18,750	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The stock option is fully vested and exercisable.

3. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.

4. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.

5. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.